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The highly pathogenic (HP) H5N1 inﬂuenza virus is endemic in many countries and has a great potential
for a pandemic in humans. The immune-enhancing prowess of ginseng has been known for millennia.
We aimed to study whether mice and ferrets fed with Red Ginseng could be better protected from the
lethal infections of HP H5N1 inﬂuenza virus than the infected unfed mice and ferrets. We fed mice and
ferrets with Red Ginseng prior to when they were infected with HP H5N1 inﬂuenza virus. The mice and
ferrets fed with a 60-day diet containing Red Ginseng could be protected from lethal infections by HP
H5N1 inﬂuenza virus (survival rate of up to 45% and 40%, respectively). Interferon-a and -g antiviral
cytokines were signiﬁcantly induced in the lungs of mice fed Red Ginseng, compared to mice fed an
unsupplemented diet. These data suggest that the diet with the immune-enhancing Red Ginseng could
help humans to overcome the infections by HP H5N1 inﬂuenza virus.
opyright  2013, The Korean Society of Ginseng, Published by Elsevier. Open access under CC BY-NC-ND license. 1. Introduction
Inﬂuenza viruses belong to the Orthomyxoviridae with genomic
negative-sense ribonucleic acid. They are classiﬁed as A, B, and C by
antigenic differences in their nucleocapsid (NP) and matrix (M)
proteins [1]. Inﬂuenza A viruses are circulating in aquatic birds and
have been responsible for human pandemics. Sixteen subtypes of
hemagglutinin (HA) and nine subtypes of neuraminidase (NA) of
inﬂuenzaAviruseshave thus far beendescribed in aquatic birds [2,3].
Inﬂuenza pandemics in humans by inﬂuenza A viruses occur
three to four times per century. During the 20th century, humans
experienced three pandemics including the Spanish pandemic by
avian-like H1N1 inﬂuenza virus in 1918, the Asian pandemic by the
reassorted H2N2 inﬂuenza virus in 1957, and the Hong Kong
pandemic by the reassorted H3N2 inﬂuenza virus in 1968 [4e9].
Among them, the Spanish pandemic was exceptional in terms of its
mortality, with over 20 million human deaths [4,5]. In this century,
a pandemic involving reassorted H1N1 inﬂuenza virus containingsearch, College of Veterinary Med
Ginseng, Published by Elsevier. Opthe human, avian, and swine-origin genomes of inﬂuenza A virus
has occurred in 2009 [10].
Highly pathogenic (HP) H5N1 inﬂuenza virus has the potential
to become a pandemic inﬂuenza virus in humans, because this vi-
rus continues to infect humans and is global in its occurrence. HP
H5N1 inﬂuenza virus has successfully negotiated the species bar-
rier from poultry to humans, killing six of 18 infected humans in
Hong Kong in 1997 [11]. Since 2003, the virus has spread to many
countries including Indonesia, Pakistan, Thailand, and Vietnam
[12e14]. As of July 5, 2013, 377 of 633 infected humans have died
from infections caused by HP H5N1 inﬂuenza virus, a mortality rate
of over 59%, despite the intensive care the patients received [15].
The clinical signs of human infection with HP H5N1 inﬂuenza
virus include high fever, severe diarrhea, seizures, and coma [14,16].
Efforts have been made to develop an effective vaccine to prepare
for the anticipated pandemic [17e19].
In seeking other forms of treatment, attention has turned to
medicinal plants, which have a history of human disease relieficine, Chungnam National University, 99 Dahak Ro, Yuseong Gu, Daejeon 305-764,





Fig. 1. Survival rate and body changes of mice fed with Red Ginseng against highly pathogenic (HP) H5N1 inﬂuenza virus. (A) Mice (n ¼ 20) fed with Red Ginseng extract (50 mg/kg)
for 80 d were intranasally (i.n.) challenged with HP H5N1 inﬂuenza virus [10 mouse lethal dose (10 MLD) 50/mL] and were observed for the survival rate for 14 d. (B, C) Mice
(n ¼ 20) fed with Red Ginseng extract (50 mg/kg) for 60 d were i.n. challenged with HP H5N1 inﬂuenza virus (10 MLD 50/mL) and were observed for (B) body-weight change and (C)
survival for 14 d. Groups were compared using repeated measures analysis of variance (ANOVA). *p < 0.05. **p < 0.001.
E.H. Park et al / H5N1 protection by Red Ginseng 41dating back to the Neanderthal period [20]. Botanical gardens
established to grow medical plants date back to at least the 16th
century [21]. Use of herbal medications in the United States
began in the early colonial days, when women provided their
family with health care. In 1974, the World Health Organization
(WHO) recommended the use of herbal medicines in developing
countries, whose modern medical infrastructure can be deﬁcient
[22].
Panax ginseng has been used as a traditional medicine in China
and Korea for over 2,000 years and has been suggested to enhance
immune responses, memory, and physical capabilities [23e25].
Ginseng saponins (ginsenosides) are the main substances in the
total extracts of ginseng and over 30 ginsenosides have been
identiﬁed in Panax ginseng [26]. The pharmacological effects of
ginseng have been reported in the central nervous, cardiovascular,
endocrine, and immune systems [27].
The present study was undertaken to investigate whether di-
etary treatment with Red Ginseng could aid in the survival from
lethal infections of HP H5N1 inﬂuenza virus and the underlying
mechanisms of the protection. For these purposes, mice and ferret
models were used.2. Materials and methods
2.1. Virus and Red Ginseng
The HP H5N1 inﬂuenza virus, A/Vietnam/1203/04 (clade 1), was
kindly provided by theWHO Collaborating Center for Inﬂuenza, the
United States Centers for Disease Control and Prevention. HP H5N1inﬂuenza virus was grown in 10-d-old hen eggs (Dukhee farm,
Icheon, Republic of Korea) prior to use. All viral experiments were
performed in a Biosafety Level-3 (BSL-3) facility approved by the
Korean government. Red Ginseng (Panax ginseng Meyer) extracts
were provided by the Korean Ginseng Co, Daejeon. Korean Red
Ginseng (KRG) extract was prepared from the roots of a 6-yr-old
fresh Panax ginseng Meyer grown in Korea. Red Ginseng was made
by steaming fresh ginseng at 90e100C for 3 h and then drying at
50e80C. Red Ginseng extract was prepared from the Red Ginseng
water extract, which was extracted at 85e90C for 8 h using three
cycles of hot water circulation. The ingredients of the Red Ginseng
(Panax ginsengMeyer) extracts included 0.71 mg/g of Radical g (Rg)
1, 0.93 mg/g of Radical e (Re), 1.21 mg/g of Radical f (Rf), 0.78 mg/g
of Radical h (Rh)1, 1.92 mg/g of Rg2(s), 1.29 mg/g of Rg2(r), 4.62
mg/g of Radical b (Rb)1, 2.41 mg/g of Radical c (Rc), 1.83 mg/g of
Rb2, 0.89 mg/g of Rd, 2.14 mg/g of Rg3(s), and 0.91 mg/g of Rg3(r).
The total content of the extracts was 19.66 mg/g.2.2. Ethics statement
This study was carried out in strict accordance with the rec-
ommendations in the Guide for the Care and Use of Laboratory
animals of the Korean Veterinary Research and Quarantine Service.
The protocol was approved by the Committee on the Ethics of
Animal Experiments of Chungnam National University. All surgery
was performed under Zoletil anesthesia (Virbac Laboratories, Crros,
France), and all efforts were made to minimize suffering. Animals
were fed with enough foods and water. The infected animals were








Fig. 2. Viral titers in the lungs and brains of mice fed with Red Ginseng and challenged
with highly pathogenic (HP) H5N1 inﬂuenza virus. Mice fed with Red Ginseng extract
(50 mg/kg) for 60 d were intranasally (i.n.) challenged with HP H5N1 inﬂuenza. The
surviving mice (n ¼ 5) were euthanized prior to when (A) the tissues of lungs and (B)
brains were collected, homogenized, and suspended in phosphate buffered saline
(PBS). The tissue supernatants were serially diluted and were inoculated into the
fertilized eggs prior to when viral titers were determined by log10 egg infectious dose
(EID) 50/mL. Groups were compared using repeated measures analysis of variance
(ANOVA). 1) We could not detect viruses on 9 d and 14 d post challenge (d.p.c.) because
all control mice died. *p < 0.05. **p < 0.001.
J Ginseng Res 2014;38:40e46422.3. Treatment of mice with Red Ginseng extract and HP H5N1
inﬂuenza virus challenge
Three-to-four wk old female mice (NaraBio, Seoul, Republic of
Korea) (BALB/c) were fed a daily diet containing Red Ginseng
extract (50 mg/kg body weight) for up to 80 d prior to intranasal
challenge with 10 mouse lethal dose of 50/mL (10 MLD 50/mL) of
virus.
2.4. Time-course survival
Mice fed (n ¼ 10 per group) as described above were challenged
with HP H5N1 inﬂuenza virus as described above 3 d, 7 d,15 d, 30 d,
60 d, and 80 d after commencement of the diet. Survival rates were
observed for 14 d postinfection (d.p.i.).
2.5. Body weight change and survival rate of mice fed Red Ginseng
extract for 60 d
Mice (n ¼ 20 per group) were fed as described above and
challenged with HP H5N1 inﬂuenza virus 60 d after commence-
ment of the diet. Body weights of the surviving mice were
determined for 14 d.p.i., or until death. Similarly, age-matched
mice not fed with Red Ginseng extract were used as comparative
controls.2.6. Determination of tissue viral titers in mice
Mice (n ¼ 10 per group) were fed and challenged with the virus
as described above. Surviving mice (n ¼ 5) were euthanized with a
high dose of Zoletil. Lung and brain tissues were immediately
collected, homogenized, and suspended in phosphate buffered sa-
line (PBS; pH 7.4; 0.05 g/mL) supplemented with 2 antibiotic-
antimycotic solution (Sigma-Aldrich, St. Louis, MO, USA). The tissue
supernatants were serially diluted 10-fold in PBS and each diluted
sample was inoculated into four 10-d-old hen eggs. The presence of
the virus in the allantoic ﬂuids of the inoculated eggs was deter-
mined by a HA assay with 0.5% turkey red blood cells (Chungnam
National University Animal Resources Center, Daejeon, Republic of
Korea). Viral titers were expressed as the log10 egg infectious dose
50/mL (log10EID 50/mL) as previously described [28]. The detection
limit of viruses was <1 log10EID 50/mL.2.7. HA assay
The allantoic ﬂuids (50 mL) were individually serially diluted
two-fold in PBS in thewells of V-bottom 96-well plates and 50 mL of
0.5% turkey red blood cells in PBS were added. Plates were incu-
bated at room temperature for 30 min prior to when hemaggluti-
nation was evaluated.2.8. Microscopic examination of mouse lung tissue
Mice (n ¼ 10 per group) were fed and challenged with the virus
as described in the body weight determination experiment. The
lungs of the surviving mice (n ¼ 3) were immediately collected and
the lung tissue was submerged in 10% neutral buffered formalin
and embedded in parafﬁn. Five micrometer-thick sections were cut
and stained with hematoxylin and eosin (H&E) stain using a stan-
dard protocol. The stained tissue sections were evaluated under a
DP70 light microscope (Olympus, Tokyo, Japan).2.9. Measurement of lung inﬂammatory cytokines in mice
Mice (n ¼ 10 per group) were fed and challenged with the virus
as described in the body weight determination experiment. The
surviving mice (n ¼ 3) were euthanized with a high dose of Zoletil
on 3 d.p.i., 5 d.p.i., or 7 d.p.i. and the lungs was collected. The
collected lungs were homogenized in PBS and the supernatants
were collected. The collected supernatants were used for deter-
mining the amount of cytokines such as tumor necrosis factor-
alpha (TNF-a), interferon (IFN)-a, IFN-g, and interleukin (IL)-4
(R&D Systems, Minneapolis, MN, USA). The assays were performed
as described by the manufacturer. Fifty mL of sample dilution
buffer was added to each well of an enzyme-linked immunosor-
bent assay (ELISA) plate followed by 50 mL of the particular su-
pernatant. The plate was gently shaken and incubated for 30 min
at room temperature. The wells were washed with wash buffer
and 100 mL of a dilution of the particular detection antibody was
added to each well. After incubation for 1 h at room temperature,
each well was washed and 100 mL of horseradish peroxidase-
conjugated Avidin was added to each well. Following incubation
for 20 min at room temperature, each well was washed and 100 mL
of development solution was dispensed. After incubating for
15 min, 100 mL of stop solution was added to each well. The
absorbance of the ﬂuid in each well was read at 450 nm using an
ELISA plate reader (Tecan, Männedorf, Switzerland). The amount
of the individual cytokine was determined based on the standard
curve of each cytokine.
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ferrets fed with Red Ginseng extract for 60 d
Seven-to-eight wk old ferrets (Mustela putorius furo; n ¼ 10 per
group) obtained from Path Valley Farm (Spring Run, PA, USA) were
fed a daily diet containing Korean Red Ginseng extract (50 mg/kg
body weight) and were intranasally (i.n.) challenged with a 10
ferret lethal dose 50/mL (10 FLD 50/mL) of HP H5N1 inﬂuenza
virus 60 d after commencement of the diet. The body weight
change of the surviving ferrets and the survival rates of infected
ferrets were observed for 14 d.p.i. Similarly, age-matched ferrets
that were not fed with Red Ginseng extract were used as controls
for comparison.
2.11. Statistical analysis
Groups of data were analyzed by repeated measures analysis of
variance (ANOVA) using pairing of samples with IBM SPSS version
20 (International Business Machines Corp, New York, USA). The
differences between the Red Ginseng administered and the control
were considered along with time and interaction between both.
Any analyses showing p < 0.05 were considered signiﬁcant.
3. Results
3.1. Protective efﬁcacy of Red Ginseng in mice against HP H5N1
inﬂuenza virus
Given that ginseng is an immune stimulator, it was of interest
to determine whether mice fed with Red Ginseng could be pro-
tected from the lethal infections of HP H5N1 inﬂuenza virus. The
effects of time-course feeding of Red Ginseng were evaluated in
mice (Fig. 1A). The survival rate of mice increased when the time
of ginseng feeding was longer. None of the 20 mice fed for 3 d orFig. 3. Evaluation of pathological damage to the lungs of mice fed with Red Ginseng foll
intranasally (i.n.) challenged with highly pathogenic (HP) H5N1 inﬂuenza virus and the surv
Lung tissues were cut and stained with hematoxylin and eosin (H&E) stain. Lung tissues of (
inﬂuenza virus, and (C), and control mice infected with HP H5N1 inﬂuenza virus are show5 d prior to the challenge with the lethal H5N1 inﬂuenza virus
survived, whereas three (15% survival rate), seven (35% survival
rate), nine (45% survival rate), and nine (45% survival rate) out of
20 mice fed for 15 d, 30 d, 60 d, and 80 d prior to the lethal
challenge with H5N1 inﬂuenza virus survived, respectively. A Red
Ginseng feeding period of 60 d was subsequently used, because
the efﬁcacy of Red Ginseng for the survival rate of mice against HP
H5N1 inﬂuenza virus was optimal. After mice fed with Red
Ginseng for 60 d were challenged with HP H5N1 inﬂuenza virus,
the temporal changes in body weight and survival rates were
determined (Fig. 1B, C). The surviving mice displayed up to a 20%
reduction in body weight, whereas the control mice displayed up
to a 25% reduction in body weight until 5 d.p.i., when all control
mice had died (Fig. 1B). The survival rate of mice fed with Red
Ginseng was initially 80%, but declined to 45% by the ﬁnal day of
observation (14 d.p.i.; Fig. 1C).
Viral titers in the lungs and brains of control mice or mice fed
with Red Ginseng were determined following the challenge with
HP H5N1 inﬂuenza virus. The viral titers in the lungs of Red
Ginseng-fed survived mice peaked at 5 d.p.i. with 5.0 EID 50/mL,
and were under the detection limit of 1 EID 50/mL on 14 d.p.i. Viral
titers in control mice peaked at 7 d.p.i. with 8.0 EID 50/mL (Fig. 2A).
The viral titers in the brains of Red Ginseng-fed survived mice
peaked at 5 d.p.i. with 2.0 EID 50/mL and were under the detection
limit (1 EID/mL) at 14 d.p.i., whereas the titer of unfed mice peaked
on 7 d.p.i. with 5.5 EID 50/mL (Fig. 2B).
Lung tissues of mice were stained with H&E 5 d after the chal-
lenge with HP H5N1 inﬂuenza to evaluate the pathological damage.
Lung tissue obtained from Red Ginseng-fed, virus-challenged mice
displayed an appearance consistent with mild pneumonia with
some lymphocyte inﬁltration (Fig. 3B), whereas tissue obtained
from the control virus-challenged mice displayed severe interstitial
pneumonia with heavy lymphocyte inﬁltration and some mucus in
the bronchioles (Fig. 3C).owing viral challenge. Mice fed with Red Ginseng extract (50 mg/kg) for 60 d were
iving mice were euthanized on 5 d postinfection (d.p.i.), and the lungs were collected.









Fig. 4. Evaluation of cytokine induction in the lungs of mice fed with Red Ginseng. Mice fed with Red Ginseng extract (50 mg/kg) for 60 d were intranasally (i.n.) challenged with
highly pathogenic (HP) H5N1. The surviving mice (n ¼ 3) were euthanized on 3 d, 5 d, or 7 d postinfection (d.p.i.), and the lungs were collected. The collected lungs were ho-
mogenized in phosphate buffered saline (PBS) and the induced amount of cytokines of (A) tumor necrosis factor-alpha (TNF-a), (B) interferon-a (IFN-a), and (C) IFN-gwere detected.
Groups were compared using repeated measures analysis of variance (ANOVA). *p < 0.05. d.p.c., days post challenge.
J Ginseng Res 2014;38:40e46443.2. Evaluation of inﬂammatory cytokines in the lungs of mice
The inﬂammatory cytokines such as TNF-a, IFN-a, IFN-g, and IL-
4 in the lungs of mice were measured to discern the possible
mechanism by which Red Ginseng aided mice in surviving a lethal
challenge of the HP H5N1 inﬂuenza virus. The induction of the pro-
inﬂammatory cytokine TNF-a was similar between control mice
and mice fed with Red Ginseng following the virus challenge
(Fig. 4A). However, IFN-a and IFN-g antiviral cytokines were
induced much more in mice fed Red Ginseng than in control mice.
IFN-a peaked on 3 d.p.i. (450 pg/mL; Fig. 4B). The IFN-g level in the
lungs of mice fed with Red Ginseng and control mice was 600 pg/
mL and 350 pg/mL, respectively, at 7 d.p.i. (Fig. 4C). IL-4 induction
was similar between both groups of mice (data not shown).
3.3. Protective efﬁcacy of Red Ginseng in ferrets against HP H5N1
inﬂuenza virus
Ferrets are a good animal model for human inﬂuenza virus
infection [29,30]. Presently, the body weight of surviving ferrets
that had been fed with Red Ginseng and lethally challenged with
HP H5N1 inﬂuenza virus was reduced up to 20% at 7 d.p.i., whereas
the body weight of control ferrets was reduced up to 25% at 5 d.p.i.
(Fig. 5A). The survival rate of ferrets fed with Red Ginsengapproached 40% at 14 d.p.i., the ﬁnal day of observation, whereas
none of the control ferrets lived to 14 d.p.i. (Fig. 5B).
4. Discussion
Human pandemics by new subtypes of inﬂuenza viruses are
inevitable. HP H5N1 inﬂuenza virus is such a candidate. The pre-
paredness for pandemics may include vaccine development, anti-
inﬂuenza drug development, and immune-enhancing medicine.
Ginseng has been regarded as an immune-enhancing compound in
humans for a long time. Our study provides evidence for this view.
Mice and ferrets fed with Red Ginseng could be protected from
lethal challenges of HP H5N1 inﬂuenza virus.
When we tested the time-course effects of Red Ginseng in mice
against HP H5N1 inﬂuenza virus, feeding for at least 15 d was
necessary for protection, suggesting that Red Ginsengmay act as an
immune stimulator rather than a therapeutic agent. This view is
entirely consistent with a variety of previous studies [24,31e34].
Repeated oral administration of Panax ginseng extract to mice
resulted in protection from the infections of Semliki forest virus up
to 34e40% [24]. A study with Chinese herbal medicinal ingredients
containing ginsenosides from ginseng showed that the inoculation
of rabbits with a mixture of rabbit hemorrhagic disease (RHD)





Fig. 5. Body-weight change and survival rate of ferrets fed with Red Ginseng. Ferrets
(n ¼ 10) fed with Red Ginseng extract (50 mg/kg) for 60 d and intranasally (i.n.)
challenged with 10 ferret lethal dose (FLD) 50/mL of highly pathogenic (HP) H5N1
inﬂuenza virus were observed for (A) body-weight change and (B) survival rate for
14 d. Groups were compared using repeated measures analysis of variance (ANOVA).
*p < 0.05. **p < 0.001. d.p.c., days post challenge.
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mRNA by T lymphocytes [31]. A study that assessed the immune
enhancing prowess of ginsenoside Rg1 from Panax ginseng using
sheep red cells as an antigen showed that the number of spleen
plaque-forming cells, titers of serum hemagglutinin, and the
number of antigen-reactive T cells could increase in mice [32].
When ginsenoside Re from the root of ginseng was inoculated into
mice with split-inactivated H3N2 inﬂuenza virus antigen, serum
antibodies, lymphocyte proliferation, and the secretion of IFN-g
and IL-5 were enhanced [33]. Ginseng may also be beneﬁcial for
those infected with the human immunodeﬁciency virus; long-term
ginseng use has been linked to slowed depletion of CD4 T lym-
phocytes in such patients [34].
The present study demonstrates that mice and ferrets fed with
Red Ginseng could be protected from the lethal challenges of HP
H5N1 inﬂuenza virus. The results hold out the potential that Red
Ginseng may contribute to protecting humans from pandemic
inﬂuenza virus prior to when the pandemic vaccine or an effective
anti-inﬂuenza drug is available. In the event of such a pandemic, an
estimated 30% of the global human population would be at risk of
infection, because most humans do not have prior immunity to
pandemic inﬂuenza virus. Considering the vast geographic distri-
bution of HP H5N1 inﬂuenza virus and its ability to infect humans,
H5N1 inﬂuenza virus is a prime candidate as a pandemic cause
[35,36]. During such an event, daily consumption of Red Ginseng
may increase the likelihood of human survival from exposure to a
lethal dose of HP H5N1 inﬂuenza virus, at least until an effective
vaccine becomes available and prophylactic protection can be
established. The pandemic vaccine can be developed only after thepandemic virus is available because HP H5N1 inﬂuenza virus
continuously evolves [37]. In addition, HP H5N1 inﬂuenza virus that
is resistant to the most used anti-inﬂuenza drug, Oseltamivir, has
already emerged [38]. Our results indicate that the underlying
mechanism that feeding of mice and ferrets with Red Ginseng help
to increase the survival rate of these animals from the lethal in-
fections of HP H5N1 inﬂuenza virus may be due to the enhanced
inductions of antiviral cytokines of IFN-a and IFN-g. It is well
established that IFN-a and IFN-g could inhibit the replication of
inﬂuenza viruses [39,40]. Further studies such as cytokine pro-
duction, viral titers, and histological pathology in ferrets may be
needed to support the immune enhancing effects of Red Ginseng
against HP H5N1 inﬂuenza virus. At this moment, no commercially
available ELISA kits for measuring ferrets’ cytokines at the level of
proteins exist.
In summary, we studied the effects of Red Ginseng on protective
immunity of mice and ferrets against HP H5N1 inﬂuenza virus. Our
results suggest that taking Red Ginseng daily may contribute to
protecting humans from the lethal infections of HP H5N1 inﬂuenza
virus in the event of a pandemic by HP H5N1 inﬂuenza virus.
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